SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for SNP rs12356193

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 An Exploratory Evaluation of Interleukin 28B (IL28B) Genotype, Single Nucleotide Polymorphisms (SNP) of rs12356193, Protein and RNA Biomarkers in Serum Samples (Stored, Already Obtained From Completed Studies) From Subjects With HBe-antigen Positive or Negative Chronic Hepatitis B, Who Have Completed Therapy for Hepatitis B With Pegasys ± Lamivudine.

This retrospective study will evaluate the association of biomarkers and the treatment response of patients with chronic hepatitis B, who have completed therapy with Pegasys (peginterferon alfa-2a) ± lamivudine. For the analysis stored serum samples obtained from patients will be used; no actual patients are involved.

NCT01705704 Hepatitis B, Chronic
MeSH:Hepatitis A Hepatitis B Hepatitis B, Chronic Hepatitis
HPO:Hepatitis

An Exploratory Evaluation of Interleukin 28B (IL28B) Genotype, Single Nucleotide Polymorphisms (SNP) of rs12356193, Protein and RNA Biomarkers in Serum Samples (Stored, Already Obtained From Completed Studies) From Subjects With HBe-antigen Positive or Negative Chronic Hepatitis B, Who Have Completed Therapy for Hepatitis B With Pegasys ± Lamivudine..

Single nucleotide polymorphisms (SNP) of rs12356193 in stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine.

Primary Outcomes

Measure: Interleukin-28B (IL-28B) genotype in stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine

Time: Samples up to 72 weeks of treatment

Measure: Single nucleotide polymorphisms (SNP) of rs12356193 in stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine

Time: Samples up to 72 weeks of treatment

Secondary Outcomes

Measure: IL-28B concentration at baseline and during treatment with Pegasys +/- lamivudine from stored serum samples of patients with chronic hepatitis B

Time: Samples up to 72 weeks of treatment

Measure: Protein/RNA biomarker evaluation from stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine

Time: Samples up to 72 weeks of treatment

HPO Nodes

HP:0012115: Hepatitis
Genes 91
SERPINA1 RFXANK RFXAP SPIB HSD3B7 CD3D MET TP53 PGM1 IL17F IL17RC BLNK CD79A CD247 STAT1 IL21R FOXP3 IL12RB1 KRT8 FASLG ATP7B IGF2R CYP7A1 CD3E TBX19 BTK RFXANK ALMS1 CASP10 ATP7B C1S GUSB XIAP FAS IL17RA PIK3CA IGHM RASGRP1 MMEL1 TTC7A TCF3 CIITA GPR35 PIK3R1 MST1 CIITA AIRE SLC25A15 TPP2 GLIS3 IRF5 XIAP POU2AF1 C4B VPS33B CYP7B1 SKIV2L BTK PIEZO1 RFX5 TTC7A BTK FAS TNPO3 CD40LG CASP8 ATP7A RFXAP SH2D1A VIPAS39 LRRC8A CTNNB1 PDGFRL CLEC7A SHPK TNFSF15 AXIN1 RFX5 APC PRKCD TCF4 AMACR TRAF3IP2 COG8 ITCH CD79B SLC25A15 IGLL1 KRT18 IL12A COG6
Protein Mutations 29
A181V A92T C282Y E62D G1764A H54Y H58C H63D L28M L31M L528M M204I M204V M28L M552I M552V N236T N370S P1028S P58A Q215S Q30H Q54H Q62E Q80K R30H Y93C Y93F Y93H
SNP 20
rs10813831 rs1127354 rs11795404 rs12356193 rs12979860 rs12992677 rs17037122 rs179008 rs2066842 rs2067085 rs2464266 rs3853839 rs41308230 rs4588 rs5743844 rs6592052 rs7041 rs7270101 rs7549785 rs8099917